Vimta Labs, a leading provider of multi-disciplinary contract research and testing services in India, received minor setback during the third quarter ended December 2005 due to almost stagnant sales and higher expenditure. Its net profit declined to Rs 3.21 crore during the quarter ended December 2005 from Rs 3.61 crore in the corresponding period of last year. The company's net sales increased marginally to Rs 13.64 crore from Rs 13.07 crore. The earning per share worked out to Rs 8.91 as against Rs 10 in the last period.

The company's net profit for the nine months period declined to Rs 10.39 crore from Rs 11.03 crore in the similar period of last year. The company's net sales for the nine months period improved to Rs 39.95 crore from Rs 38.84 crore.

The company is now planning to raise funds up to Rs 125 crore to part finance its second phase of the expansion programme through issue of equity shares or other instruments like GDR/ADR/Warrants convertible into equity shares.

Vimta Labs is the preferred choice for many market leaders across the globe on account of its international quality systems, world class infrastructure and expert human resources. It has won many International accreditations and Quality certifications such as ISO/IEC 17025-1999.

Vimta provides contract research and testing services in the areas of clinical research, pre-clinical (animal) studies, clinical reference lab services, environmental assessments and analytical testing of a wide variety of products.